The Bank of Japan Governor's speech was "hawkish," stating that if the economy develops as expected, interest rates will continue to be raised, with specific decisions to be made after assessing the impact of the current rate hike.
BlockBeats News, on December 19, Bank of Japan Governor Kazuo Ueda stated at this afternoon's monetary policy press conference in the East 8th District that while Japan's economy shows some signs of weakness, it is moderately recovering. If the economy and prices develop as expected, and as both improve, the Bank of Japan will continue to raise policy interest rates.
After this rate hike, Japan's benchmark interest rate has risen from 0.50% to 0.75%, reaching its highest level since 1995 and marking Japan's official departure from the ultra-low interest rate era that lasted for 30 years. Regarding this, Kazuo Ueda commented: "There is no special significance to short-term interest rates being at a 30-year high; we will closely monitor the impact of the latest rate changes."
Regarding future plans, Kazuo Ueda stated: "The pace of monetary adjustment will depend on the outlook for the economy, prices, and finance. There is still some distance to the lower bound of the neutral interest rate range. Currently, there is no sign of the strong tightening effect seen in previous rate hikes. We will decide whether to raise rates again after assessing the impact of the increase to 0.75% on the economy and prices. If wage increases continue to be passed on to prices, further rate hikes are indeed possible."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitcoin Trades Around $86K as FOMO Hits Highest Level Since 2024

siRNA rising star ADARx (ADRX.US) launches $350 millions IPO, AbbVie subscribes to 4.9% of shares with a maximum investment of $100 millions
ADARx plans to raise $350 millions and list on Nasdaq. AbbVie will invest up to $100 millions to acquire a 4.9% stake, with a median valuation of $1.8 billions.
Roche (RHHBY.US) weight loss injection shows positive mid-term trial results: average weight loss of 15.5% over 48 weeks, blood sugar levels drop by 2.65%.
The experimental weight-loss injection enicepatide simultaneously lowered blood sugar and body weight in overweight or obese patients with type 2 diabetes during a mid-stage clinical trial.
SPAC company Silicon Valley Acquisition II (SVATU.US) applies for US stock IPO, aiming to raise up to 220 millions USD.
The blank-check company (SPAC) Silicon Valley Acquisition II submitted a filing to the U.S. Securities and Exchange Commission (SEC) on Monday, planning to raise up to 220 millions USD through an initial public offering (IPO).
